The Why Behind
We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality.
Our Story Begins with Unconventional Thinking
For more than 20 years, scientists and industry were limited in their understanding of what LNPs could do, which is why they’ve only been able to be delivered to the liver. The ability to directly target specific organs and cells beyond the liver has long been the holy grail for genetic medicines.
To crack this code, our co-founder, Professor Daniel J. Siegwart, Ph.D. of the University of Texas, had the scientific vision and courage to break away from conventional thinking. Unlike first-generation LNPs, which are made of four lipids, he had the insight to add a biochemically distinct fifth lipid to help the body “sort” and direct the LNPs to targeted cells and organs — with the ability to bypass the liver, if desired.
This marked the beginning of the SORT (Selective ORgan Targeting) LNP. In 2020, we merged the pioneers behind the SORT technology with renowned mRNA experts to create ReCode. Today, the SORT LNP platform is the foundation of our growing clinical pipeline of next-generation generic medicines.
We are pioneering disease-modifying mRNA therapeutics that address the underlying cause of rare and common genetic diseases.Our lead programs are focused on primary ciliary dyskinesia and cystic fibrosis.
We are also expanding and diversifying our pipeline using SORT LNP technology to develop potential therapies for genetic diseases, including muscular, central nervous system, liver, infectious disease and oncology indications.